Background/Objectives: Minoxidil, in addition to its vasodilatory effect, has also immunomodulatory properties that may be partially responsible for its efficacy in alopecia areata. The aim of the study was to evaluate the efficacy of monotherapy with topical or oral minoxidil in alopecia areata. Methods: A systematic review and meta-analysis of the efficacy of monotherapy with minoxidil in alopecia areata was conducted following the PRISMA guidelines. Efficacy of minoxidil in alopecia areata was evaluated separately for three groups of the patients: (1) treated with 5% topical minoxidil, (2) less than 5% topical minoxidil, and (3) oral minoxidil. Therapeutic response was defined as any regrowth of terminal hair. Results: Of 244 articles, 13 were considered eligible for the further analysis. The study included 372 patients with alopecia areata (338 using topical minoxidil and 34 taking oral minoxidil). The mean time of treatment ranged from 2 to 60 weeks (mean: 27 weeks). The response rate for 5% topical was 82% (95% CI 0.7–0.93) and 58% (95% Cl 0.5–0.67) for the less than 5% topical minoxidil group. For the group of patients treated orally, the response rate was 82%. Conclusions: Minoxidil, both topical and oral, may be beneficial in monotherapy in patients with alopecia areata. 5% topical minoxidil is characterized by significantly higher efficacy compared to minoxidil at a lower concentration. There are no sufficient data to recommend minoxidil as a first-line therapeutic option for alopecia areata.
In recent years, a series of articles has been published concerning magnetic resonance imaging (MRI) studies in a group of patients exposed to manganism, specifically factory workers, welders, and individuals with liver diseases, as well as those abusing home-produced ephedrone. Some potential symptoms of manganese toxicity include motor disturbances, neurocognitive problems, sleep disorders, and psychosocial changes. Despite various publications on MRI research in individuals with an elevated risk of manganism, there is a noticeable absence of a comprehensive review in this field. The detection of the accumulation of manganese in the brain through MRI can confirm the diagnosis and guide appropriate treatment. Due to the high cost of determining manganese ion levels in biological material, an additional aim of the manuscript was to identify simple medical laboratory parameters that, when performed concurrently with MRI, could assist in the diagnosis of manganism. Among these types of parameters are the levels of bilirubin, magnesium, liver enzymes, creatinine, hemoglobin, and hematocrit.
17 March 2025 in Archives of Dermatological Research
Background/Objectives: Artificial intelligence (AI) is gaining importance in clinical pharmacology, supporting therapeutic decisions and the prediction of drug interactions, although its applications have significant limitations. The aim of the study was to evaluate the accuracy of the responses of four large language models (LLMs), namely ChatGPT-4o, ChatGPT-3.5, Gemini Advanced 2.0, and DeepSeek, in the field of clinical pharmacology and drug interactions, as well as to analyze the impact of prompting and questions from the National Specialization Examination for Pharmacists (PESF) on the results. Methods: In the analysis, three datasets were used: 20 case reports of successful pharmacotherapy, 20 reports of drug–drug interactions, and 240 test questions from the PESF (spring 2018 and autumn 2019 sessions). The responses generated by the models were compared with source data and the official examination key and were independently evaluated by clinical-pharmacotherapy experts. Additionally, the impact of prompting techniques was analyzed by expanding the content of the queries with detailed clinical and organizational elements to assess their influence on the accuracy of the obtained recommendations. Results: The analysis revealed differences in the accuracy of responses between the examined AI tools (p < 0.001), with ChatGPT-4o achieving the highest effectiveness and Gemini Advanced 2.0 the lowest. Responses generated by Gemini were more often imprecise and less consistent, which was reflected in their significantly lower level of substantive accuracy (p < 0.001). The analysis of more precisely formulated questions demonstrated a significant main effect of the AI tool (p < 0.001), with Gemini Advanced 2.0 performing significantly worse than all other models (p < 0.001). An additional analysis comparing responses to simple and extended questions, which incorporated additional clinical factors and the mode of source presentation, did not reveal significant differences either between AI tools or within individual models (p = 0.34). In the area of drug interactions, it was also shown that ChatGPT-4o achieved a higher level of response accuracy compared with the other tools (p < 0.001). Regarding the PESF exam questions, all models achieved similar results, ranging between 83 and 86% correct answers, and the differences between them were not statistically significant (p = 0.67). Conclusions: AI models demonstrate potential in the analysis of clinical pharmacology; however, their limitations require further refinement and cautious application in practice.
5 July 2025 in Archives of Dermatological Research